Laurus Labs inaugrates new RnD center at Telangana
Hyderabad: Laurus Labs Ltd. a research and development driven pharmaceutical and biotech company in India has announced the inauguration of its state of the art new R&D center at IKP Knowledge Park, Plot No DS15, Kolthur Shamirpet Medchal Telangana.
The total investment incurred for setting-up the new R&D is Rs 250 Crore. The 2,00,000 Square foot facility is equipped with modern laboratories and infrastructure. R&D Center is developed to support the CDMO business of Laurus Labs. The facility will provide job opportunities to over 800 people.
The facility was inaugurated by Honourable Shri Duddilla Sridhar Babu Garu, Minister of Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs - Government of Telangana along with Dr. Satyanarayana Chava, Founder & CEO Laurus Labs along with other senior management team.
On the occasion of the inauguration Dr. Satyanarayana Chava, Founder & CEO Laurus Labs, said "This will be our 5th R&D center and the new R&D center will be a testimonial to our commitment to innovation and excellence. We believe that this facility will enable us to develop ground breaking solutions that will address unmet medical needs".
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company. Laurus has a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. Laurus also offers integrated Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation. Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UKMHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.